Skip to content
AnalystLens

Idex 8-K Report, Financial Results (May 1, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed May 1, 2025
Period End
May 1, 2025
Security
IEX
In the record · 2016–202610-K1110-Q338-K119

IEX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Jan ’18Jan ’18
  2. Material agreement8-K · Apr ’20Apr ’20
  3. Leadership change8-K · Sep ’22Sep ’22
  4. Material agreement8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.

IDEX Corporation reported first-quarter 2025 results for the three months ended March 31, 2025, in a press release furnished as Exhibit 99.1 under Item 2.02.

Orders were $871.9 milliona, up 6% from $820.3 million, with organic orders up 1%. Net sales were $814.3 million, up 2% from $800.5 million, but organic sales decreased 1%, driven by lower volumes in certain Fluid & Metering Technologies and Health & Science Technologies businesses. Reported diluted EPS was $1.26 versus $1.60 a year earlier, and adjusted diluted EPS was $1.75 versus $1.88.

Net income attributable to IDEX was $95.5 millionb, down from $121.4 million, reflecting higher interest expense, depreciation, a higher effective tax rate, and higher restructuring and amortization costs. Management maintained its full-year 2025 organic sales growth guidance of 1% to 3% and GAAP diluted EPS guidance of $6.56 to $6.95 (adjusted diluted EPS of $8.10 to $8.45). For the second quarter, it guided to GAAP diluted EPS of $1.60 to $1.72 and adjusted diluted EPS of $1.95 to $2.05, based on organic sales growth of 0% to 2%.

Management said it identified an additional $20 millionc of cost containment actions to offset potential tariff-related volume pressure and later-stage demand pressure, and that platform optimization efforts are on track for a total of $43 million impact in 2025. Cash flow weakened, with operating cash flow of $105.7 million (down from $156.6 million) and free cash flow of $91.4 million (down from $136.6 million), reflecting higher inventory build and interest payments on senior notes issued to fund the Mott acquisition. The company repurchased 256,159 shares for $50.0 million in February 2025 and had $249.0 million outstanding under its revolving credit facility at March 31, 2025, after repayments in January and April 2025.

Key Highlights

  1. Orders of $871.9 million were a record, up 6% reported and 1% organically, the fourth consecutive quarter of positive organic order performance.
  2. Net sales of $814.3 million rose 2% reported but declined 1% organically, with the Mott acquisition contributing to reported growth.
  3. Adjusted EBITDA was $208.0 million, roughly flat versus $208.3 million, with an adjusted EBITDA margin of 25.5% versus 26.0%.
  4. Diluted EPS was $1.26 (down from $1.60) and adjusted diluted EPS was $1.75 (down from $1.88).
  5. Full-year 2025 guidance maintained: organic sales growth of 1% to 3% and GAAP diluted EPS of $6.56 to $6.95.
  6. Second-quarter 2025 guidance calls for GAAP diluted EPS of $1.60 to $1.72 and organic sales growth of 0% to 2%.
  7. Free cash flow fell to $91.4 million from $136.6 million, and $50.0 million was spent repurchasing 256,159 shares.

Frequently Asked Questions

  1. Did IDEX meet expectations in the first quarter of 2025?

    Management said all segments exceeded its expectations for revenue and profitability. Organic sales still declined 1%, and adjusted diluted EPS fell to $1.75 from $1.88.

  2. Did IDEX change its full-year 2025 outlook?

    No. The company maintained its full-year organic sales growth guidance of 1% to 3% and its diluted EPS guidance ranges, which are GAAP diluted EPS of $6.56 to $6.95 and adjusted diluted EPS of $8.10 to $8.45.

  3. What is management doing about tariff and demand pressures?

    The company identified an additional $20 million of cost containment actions for 2025 to offset potential tariff-related volume pressure and later-stage demand pressure. Platform optimization and delayering efforts are on track for a total of $43 million impact in 2025.

  4. Why did cash flow decline in the quarter?

    Operating cash flow fell to $105.7 million from $156.6 million, mainly due to larger inventory increases to support planned production and interest payments on the 4.950% senior notes issued in 2024 to fund the Mott acquisition.

  5. Which segments drove the quarter's results?

    Health & Science Technologies net sales rose 10% to $341.5 million on the Mott acquisition, though its organic sales fell 1%. Fluid & Metering Technologies net sales fell 7% to $290.5 million, with organic sales down 4%. Fire & Safety/Diversified Products net sales rose 4% to $184.3 million, with organic sales up 5%.